Since the first oligonucleotide (OGNT) drug was approved by the US Food and Drug Administration (FDA) for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology and development methods; however, due to the complexity and sensitivity of oligonucleotides, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.
Join this webinar to learn about the current and future state of oligonucleotides from a bioanalytical industry expert as they discuss:
- Current and future state of the bioanalysis of oligonucleotides
- Common approaches to bioanalysis of oligonucleotides
- Evaluating and selecting the optimal and strategic approach
Speaker
Troy Voelker, PhD, Director of Laboratory Operations, Aliri
Troy Voelker is the Director of Laboratory Operations at Aliri in Salt Lake City where he leads all of the lab divisions including method development, method validation, instrument operations, and production groups. He obtained his Ph.D. in synthetic organic chemistry with and a post doctorate in medicinal drug development and drug metabolism. He has been working in the bioanalytical industry for over 17 years and has developed assays for large and small molecules with extensive experience on both triple quadrupoles and high resolution accurate mass platforms. He is the Aliri SME for oligonucleotide bioanalysis in which he has lead development and validation for this therapeutic class for the past 10 years.
Message PresenterWho Should Attend?
- Chief Scientific Officer
- Chief Development Officer
- Chief Technology Officer
- Chief Operating Officer
- CEO/Founder/Managing Director
- Head of Pharmaceutical Development
- VP/Head/Director/Manager/Senior Manager
- Head/Director of Discovery/Drug Product
- Head/Director of Research
- Lab Director/Lab Manager
- Principal Scientist
- Senior Scientist
- Senior Researcher
- Head of Chemistry/Biology
- Director/Manager of R&D
What You Will Learn
Attendees will gain insights into:
- Current and future state of the bioanalysis of oligonucleotides
- Common approaches to bioanalysis of oligonucleotides
- Evaluating and selecting the optimal and strategic approach
Xtalks Partner
Aliri
Aliri is a leading bioanalytical contract research organization with three sites in Colorado Springs, Colorado, Salt Lake City, Utah and Loos, France. We provide a range of bioanalytical lab, spatial bioanalysis, and spatial biology solutions to pharmaceutical companies for all stages of the drug development process. With industry-leading science and regulatory compliance, our team helps pharma and bio companies advance their molecule from discovery through clinical development and NDA approval.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account